An in vitro model of the macrophage-endothelial interface to characterize CAR T-cell induced cytokine storm

• Published in: Scientific reports Vol. 13; no. 1; p. 18835
• Main Authors: Rosen, Robert S., Yang, Jason H., Peña, Juan S., Schloss, Rene, Yarmush, Martin L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/61/51/1844; 692/4028/67/1059/2325; 692/420/256/2516; 692/699/249/2510; 692/700/565/2194; Cell therapy; Chimeric antigen receptors; Corticoids; Corticosteroids; Cytokine Release Syndrome; Cytokine storm; Endothelial Cells; Humanities and Social Sciences; Humans; Inflammation; Inflammation - drug therapy; Lymphocytes B; Lymphocytes T; Macrophages; Malignancy; multidisciplinary; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Science; Science (multidisciplinary); Stat3 protein; T-Lymphocytes; Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-46114-y

Chimeric Antigen Receptor (CAR) T-cell therapy is a highly effective treatment for B-cell malignancies but limited in use due to clinically significant hyperinflammatory toxicities. Understanding the pathophysiologic mechanisms which mediate these toxicities can help identify novel management strategies. Here we report a novel in vitro model of the macrophage-endothelial interface to study the effects of CAR T-cell-induced cytokine storm. Using this model, we demonstrate that macrophage-mediated inflammation is regulated by endothelial cell activity. Furthermore, endothelial inflammation occurs independently of macrophages following exposure to CAR T-cell products and the induced endothelial inflammation potentiates macrophage-mediated inflammatory signaling, leading to a hyperinflammatory environment. While corticosteroids, the current gold standard of care, attenuate the resulting macrophage inflammatory signaling, the endothelial activity remains refractory to this treatment strategy. Utilizing a network model, coupled to in vitro secretion profiling, we identified STAT3 programming as critical in regulating this endothelial behavior. Lastly, we demonstrate how targeting STAT3 activity can abrogate endothelial inflammation and attenuate this otherwise hyperinflammatory environment. Our results demonstrate that endothelial cells play a central role in the pathophysiology of CAR T-cell toxicities and targeting the mechanisms driving the endothelial response can guide future clinical management.